Heterogeneity of intratumoral 111In-ibritumomab tiuxetan and 18F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma
Open Access
- 14 March 2015
- journal article
- research article
- Published by Springer Nature in EJNMMI Research
- Vol. 5 (1) , 10
Abstract
Background: The purpose of this study was to quantitatively evaluate the tumor accumulation and heterogeneity of 111In-ibritumomab tiuxetan (Zevalin®) and tumor accumulation of 18F-fluoro-deoxyglucose (FDG) and compare them to the tumor response in B-cell non-Hodgkin’s lymphoma patients receiving 90Y-ibritumomab tiuxetan (Zevalin®) therapy. Methods: Sixteen patients with histologically confirmed non-Hodgkin’s B-cell lymphoma who underwent 90Y-ibritumomab tiuxetan therapy along with 111In-ibritumomab tiuxetan single-photon emission computerized tomography (SPECT)/CT and FDG positron emission tomography (PET)/CT were enrolled in this retrospective study. On pretherapeutic FDG PET/CT images, the maximum standardized uptake value (SUVmax) was measured. On SPECT/CT images, a percentage of the injected dose per gram (%ID/g) and SUVmax of 111In-ibritumomab tiuxetan were measured at 48 h after its administration. The skewness and kurtosis of the voxel distribution were calculated to evaluate the intratumoral heterogeneity of tumor accumulation. As another intratumoral heterogeneity index, cumulative SUV-volume histograms describing the percentage of the total tumor volume above the percentage thresholds of pretherapeutic FDG and 111In-ibritumomab tiuxetan SUVmax (area under the curve of the cumulative SUV histograms (AUC-CSH)) were calculated. All lesions (n = 42) were classified into responders and non-responders lesion-by-lesion on pre- and post-therapeutic CT images. Results: A positive correlation was observed between the FDG SUVmax and accumulation of 111In-ibritumomab tiuxetan in lesions. A significant difference in pretherapeutic FDG SUVmax was observed between responders and non-responders, while no significant difference in 111In-ibritumomab tiuxetan SUVmax was observed between the two groups. In contrast, voxel distribution of FDG demonstrated no significant differences in the three heterogeneity indices between responders and non-responders, while 111In-ibritumomab tiuxetan demonstrated skewness of 0.58 ± 0.16 and 0.73 ± 0.24 (p < 0.05), kurtosis of 2.39 ± 0.32 and 2.78 ± 0.53 (p < 0.02), and AUC-CSH of 0.37 ± 0.04 and 0.34 ± 0.05 (p < 0.05) for responders and non-responders. Conclusions: Pretherapeutic FDG accumulation was predictive of the tumor response in 90Y-ibritumomab tiuxetan therapy. The heterogeneity of the intratumoral distribution rather than the absolute level of 111In-ibritumomab tiuxetan was correlated with the tumor response.Keywords
This publication has 29 references indexed in Scilit:
- A multivendor phantom study comparing the image quality produced from three state-of-the-art SPECT-CT systemsNuclear Medicine Communications, 2012
- Improved tumour response prediction with equivalent uniform dose in pre-clinical study using direct intratumoural infusion of liposome-encapsulated186Re radionuclidesPhysics in Medicine & Biology, 2011
- Methodology to Incorporate Biologically Effective Dose and Equivalent Uniform Dose in Patient-Specific 3-Dimensional Dosimetry for Non-Hodgkin Lymphoma Patients Targeted with 131I-Tositumomab TherapyJournal of Nuclear Medicine, 2010
- FDG–PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric studyAnnals of Oncology, 2010
- Quantitative Analysis of 90 Y Bremsstrahlung SPECT-CT Images for Application to 3D Patient-Specific DosimetryCancer Biotherapy and Radiopharmaceuticals, 2009
- 18F-FDG PET/CT for Monitoring the Response of Lymphoma to RadioimmunotherapyJournal of Nuclear Medicine, 2008
- 90Y-Ibritumomab Therapy in Refractory Non-Hodgkin's Lymphoma: Observations from 111In-Ibritumomab Pretreatment ImagingJournal of Nuclear Medicine, 2008
- High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored TreatmentJournal of Nuclear Medicine, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Summary and PerspectivesActa Oncologica, 1996